{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:52:12Z","timestamp":1785808332894,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05773-0","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:42:43Z","timestamp":1785807763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database"],"prefix":"10.1007","author":[{"given":"Shuoshuo","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"8","key":"5773_CR1","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.47391\/JPMA.20096","volume":"74","author":"S Ali","year":"2024","unstructured":"Ali S, Ilyas MA (2024) Fezolinetant: A novel NK3R antagonist for treating postmenopausal vasomotor symptoms. J Pak Med Assoc 74(8):1582. https:\/\/doi.org\/10.47391\/JPMA.20096","journal-title":"J Pak Med Assoc"},{"issue":"2","key":"5773_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH (2019) Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol 1(2):172\u2013178. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006","journal-title":"JACC CardioOncol"},{"issue":"22","key":"5773_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262211098","volume":"26","author":"AM Arnautu","year":"2025","unstructured":"Arnautu AM, Nimigean VR, Nacea-Radu CA, Tilici DM, Paun DL (2025) Menopausal hormone therapy-risks, benefits and emerging options: a narrative review. Int J Mol Sci 26(22):11098. https:\/\/doi.org\/10.3390\/ijms262211098","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5773_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","volume":"175","author":"NE Avis","year":"2015","unstructured":"Avis NE, Crawford SL, Greendale G et al (2015) Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 175(4):531\u2013539. https:\/\/doi.org\/10.1001\/jamainternmed.2014.8063","journal-title":"JAMA Intern Med"},{"key":"5773_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH (2016) A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data 3:160026. https:\/\/doi.org\/10.1038\/sdata.2016.26","journal-title":"Sci Data"},{"key":"5773_CR6","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.2023.38.S1.5732862","author":"B Beekly","year":"2023","unstructured":"Beekly B, Furman K, Burgess C et al (2023) KNDy innervation of MCH neurons modulates sleep in an estradiol-dependent manner. Physiology. https:\/\/doi.org\/10.1152\/physiol.2023.38.S1.5732862","journal-title":"Physiology"},{"issue":"7","key":"5773_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R et al (2015) Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148(7):1340\u201352.e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"issue":"9","key":"5773_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/jcph.70024","volume":"65","author":"MP Choules","year":"2025","unstructured":"Choules MP, Otsuka Y, Nielsen JC, Iwai M, Bonate PL (2025) Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between fezolinetant and CYP1A2 inhibitors. J Clin Pharmacol 65(9):1096\u20131105. https:\/\/doi.org\/10.1002\/jcph.70024","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"5773_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40264-023-01390-5","volume":"47","author":"EB Cohen","year":"2024","unstructured":"Cohen EB, Patwardhan M, Raheja R et al (2024) Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative. Drug Saf 47(4):301\u2013319. https:\/\/doi.org\/10.1007\/s40264-023-01390-5","journal-title":"Drug Saf"},{"issue":"5","key":"5773_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/17512433.2025.2495951","volume":"18","author":"L Cucinella","year":"2025","unstructured":"Cucinella L, Cassani C, Tedeschi S, Memoli S, Martini E, Nappi RE (2025) A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms. Expert Rev Clin Pharmacol 18(5):247\u2013258. https:\/\/doi.org\/10.1080\/17512433.2025.2495951","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"5773_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","volume":"30","author":"H Depypere","year":"2021","unstructured":"Depypere H, Lademacher C, Siddiqui E, Fraser GL (2021) Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 30(7):681\u2013694. https:\/\/doi.org\/10.1080\/13543784.2021.1893305","journal-title":"Expert Opin Investig Drugs"},{"key":"5773_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.maturitas.2016.06.001","volume":"91","author":"TJ de Villiers","year":"2016","unstructured":"de Villiers TJ, Hall JE, Pinkerton JV et al (2016) Revised global consensus statement on menopausal hormone therapy. Maturitas 91:153\u2013155. https:\/\/doi.org\/10.1016\/j.maturitas.2016.06.001","journal-title":"Maturitas"},{"issue":"3","key":"5773_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5114\/pm.2025.154676","volume":"24","author":"R Dhruve","year":"2025","unstructured":"Dhruve R, Singh A, Jain A, Sohal A, Schneider J (2025) Burden of steatotic liver disease in postmenopausal women: NHANES 2017\u20132020 insights. Prz Menopauzalny 24(3):156\u2013162. https:\/\/doi.org\/10.5114\/pm.2025.154676","journal-title":"Prz Menopauzalny"},{"issue":"3","key":"5773_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/dtb.2024.000070","volume":"63","author":"Drug and Therapeutics Bulletin","year":"2025","unstructured":"Drug and Therapeutics Bulletin (2025) Safety update: EMA and FDA warn of liver problems with fezolinetant. Drug Ther Bull 63(3):36. https:\/\/doi.org\/10.1136\/dtb.2024.000070","journal-title":"Drug Ther Bull"},{"issue":"9","key":"5773_CR15","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1097\/MS9.0000000000003670","volume":"87","author":"C Elendu","year":"2025","unstructured":"Elendu C, Okahia TW, Blewusi GS et al (2025) FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option. Ann Med Surg (Lond) 87(9):5373\u20135377. https:\/\/doi.org\/10.1097\/MS9.0000000000003670","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"5773_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/humupd\/dmab026","volume":"27","author":"AR Genazzani","year":"2021","unstructured":"Genazzani AR, Monteleone P, Giannini A, Simoncini T (2021) Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update 27(6):1115\u20131150. https:\/\/doi.org\/10.1093\/humupd\/dmab026","journal-title":"Hum Reprod Update"},{"issue":"7","key":"5773_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","volume":"96","author":"EB Gold","year":"2006","unstructured":"Gold EB, Colvin A, Avis N et al (2006) Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation. Am J Public Health 96(7):1226\u20131235. https:\/\/doi.org\/10.2105\/AJPH.2005.066936","journal-title":"Am J Public Health"},{"issue":"5","key":"5773_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/GME.0000000000002703","volume":"33","author":"CD Hsu","year":"2026","unstructured":"Hsu CD, Carpenter RM, Richardson G et al (2026) Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting. Menopause 33(5):529\u2013535. https:\/\/doi.org\/10.1097\/GME.0000000000002703","journal-title":"Menopause"},{"key":"5773_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-pathmechdis-051122-094016","volume":"19","author":"H Jaeschke","year":"2024","unstructured":"Jaeschke H, Ramachandran A (2024) Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annu Rev Pathol 19:453\u2013478. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051122-094016","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"5773_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/GME.0000000000002133","volume":"30","author":"A Jaroenlapnopparat","year":"2023","unstructured":"Jaroenlapnopparat A, Charoenngam N, Ponvilawan B, Mariano M, Thongpiya J, Yingchoncharoen P (2023) Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Menopause 30(3):348\u2013354. https:\/\/doi.org\/10.1097\/GME.0000000000002133","journal-title":"Menopause"},{"issue":"2","key":"5773_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12325-024-03073-8","volume":"42","author":"R Kagan","year":"2025","unstructured":"Kagan R, Cano A, Nappi RE et al (2025) Safety of fezolinetant for treatment of moderate to severe vasomotor symptoms due to menopause: pooled analysis of three randomized phase 3 studies. Adv Ther 42(2):1147\u20131164. https:\/\/doi.org\/10.1007\/s12325-024-03073-8","journal-title":"Adv Ther"},{"issue":"12","key":"5773_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40265-023-01917-1","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A (2023) Fezolinetant: first approval. Drugs 83(12):1137\u20131141. https:\/\/doi.org\/10.1007\/s40265-023-01917-1","journal-title":"Drugs"},{"key":"5773_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1280490","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Wang C, Deng A, Guo C (2023) A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system. Front Pharmacol 14:1280490. https:\/\/doi.org\/10.3389\/fphar.2023.1280490","journal-title":"Front Pharmacol"},{"key":"5773_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516449","volume":"16","author":"S Lou","year":"2025","unstructured":"Lou S, Chen H, Cui Z et al (2025) Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024. Front Pharmacol 16:1516449. https:\/\/doi.org\/10.3389\/fphar.2025.1516449","journal-title":"Front Pharmacol"},{"issue":"5","key":"5773_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051438","volume":"14","author":"B Meczekalski","year":"2025","unstructured":"Meczekalski B, Kostrzak A, Unogu C et al (2025) A new hope for woman with vasomotor symptoms: neurokinin B antagonists. J Clin Med 14(5):1438. https:\/\/doi.org\/10.3390\/jcm14051438","journal-title":"J Clin Med"},{"issue":"1713","key":"5773_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.58347\/tml.2024.1713e","volume":"66","author":"Medical Letter on Drugs and Therapeutics","year":"2024","unstructured":"Medical Letter on Drugs and Therapeutics (2024) In Brief: New Warning for Fezolinetant (Veozah) 66(1713):168. https:\/\/doi.org\/10.58347\/tml.2024.1713e","journal-title":"In Brief: New Warning for Fezolinetant (Veozah)"},{"issue":"6","key":"5773_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/GME.0000000000002354","volume":"31","author":"RE Nappi","year":"2024","unstructured":"Nappi RE, Johnson KA, Stute P et al (2024) Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause 31(6):512\u2013521. https:\/\/doi.org\/10.1097\/GME.0000000000002354","journal-title":"Menopause"},{"key":"5773_CR28","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2024) LiverTox: Fezolinetant. Available from: https:\/\/livertox.nlm.nih.gov\/Fezolinetant.htm. Accessed 20 Apr 2026"},{"issue":"4","key":"5773_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/cpt.70194","volume":"119","author":"JC Nielsen","year":"2026","unstructured":"Nielsen JC, Woodhead JL, Howell BA et al (2026) Quantitative systems toxicology modeling with DILIsym to support phase 3 dose selection for fezolinetant. Clin Pharmacol Ther 119(4):1016\u20131024. https:\/\/doi.org\/10.1002\/cpt.70194","journal-title":"Clin Pharmacol Ther"},{"key":"5773_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108291","volume":"157","author":"A Nuthi","year":"2025","unstructured":"Nuthi A, Mishra G, Dixit VA (2025) Carbene reactive metabolite explains the hepatotoxicity of the hot flashes drug fezolinetant: a DFT investigation. Bioorg Chem 157:108291. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108291","journal-title":"Bioorg Chem"},{"issue":"2","key":"5773_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.celrep.2018.06.037","volume":"24","author":"SL Padilla","year":"2018","unstructured":"Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD (2018) A neural circuit underlying the generation of hot flushes. Cell Rep 24(2):271\u2013277. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.037","journal-title":"Cell Rep"},{"key":"5773_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1251961","volume":"15","author":"Y Pan","year":"2024","unstructured":"Pan Y, Wang Y, Zheng Y, Chen J, Li J (2024) A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor. Front Pharmacol 15:1251961. https:\/\/doi.org\/10.3389\/fphar.2024.1251961","journal-title":"Front Pharmacol"},{"issue":"5","key":"5773_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2174\/187152710793361504","volume":"9","author":"N Pantaleo","year":"2010","unstructured":"Pantaleo N, Chadwick W, Park SS et al (2010) The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders. CNS Neurol Disord Drug Targets 9(5):627\u2013635. https:\/\/doi.org\/10.2174\/187152710793361504","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"11","key":"5773_CR34","doi-asserted-by":"publisher","first-page":"e1448","DOI":"10.1210\/clinem\/dgad209","volume":"108","author":"JV Pinkerton","year":"2023","unstructured":"Pinkerton JV, Redick DL, Homewood LN, Kaunitz AM (2023) Neurokinin receptor antagonist, fezolinetant, for treatment of menopausal vasomotor symptoms. J Clin Endocrinol Metab 108(11):e1448\u2013e1449. https:\/\/doi.org\/10.1210\/clinem\/dgad209","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"5773_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","volume":"34","author":"NE Rance","year":"2013","unstructured":"Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ (2013) Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 34(3):211\u2013227. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.003","journal-title":"Front Neuroendocrinol"},{"issue":"6","key":"5773_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00737-024-01456-y","volume":"27","author":"P Rani","year":"2024","unstructured":"Rani P, Zehra D, Mansoor M, Rani P (2024) FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Arch Womens Ment Health 27(6):943\u2013946. https:\/\/doi.org\/10.1007\/s00737-024-01456-y","journal-title":"Arch Womens Ment Health"},{"key":"5773_CR37","doi-asserted-by":"publisher","unstructured":"Reactions Weekly (2025) Fezolinetant-induced liver injury, monitoring recommendations. 2043(2). https:\/\/doi.org\/10.1007\/s40278-025-75283-z","DOI":"10.1007\/s40278-025-75283-z"},{"issue":"9","key":"5773_CR38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/14656566.2024.2375039","volume":"25","author":"MZ Roberts","year":"2024","unstructured":"Roberts MZ, Andrus MR (2024) Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause. Expert Opin Pharmacother 25(9):1131\u20131136. https:\/\/doi.org\/10.1080\/14656566.2024.2375039","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"5773_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women\u2019s health initiative randomized controlled trial. JAMA 288(3):321\u2013333. https:\/\/doi.org\/10.1001\/jama.288.3.321","journal-title":"JAMA"},{"key":"5773_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079525","volume":"387","author":"K Schaudig","year":"2024","unstructured":"Schaudig K, Wang X, Bouchard C et al (2024) Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ 387:e079525. https:\/\/doi.org\/10.1136\/bmj-2024-079525","journal-title":"BMJ"},{"key":"5773_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108159","volume":"193","author":"C Shapiro","year":"2025","unstructured":"Shapiro C, Wu X, Wang X et al (2025) Effect of fezolinetant on patient-reported quality-of-life outcomes: data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas 193:108159. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108159","journal-title":"Maturitas"},{"issue":"1","key":"5773_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","volume":"82","author":"J Skat-R\u00f8rdam","year":"2025","unstructured":"Skat-R\u00f8rdam J, Lykkesfeldt J, Gluud LL, Tveden-Nyborg P (2025) Mechanisms of drug induced liver injury. Cell Mol Life Sci 82(1):213. https:\/\/doi.org\/10.1007\/s00018-025-05744-3","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"5773_CR43","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","volume":"100","author":"CA Stuenkel","year":"2015","unstructured":"Stuenkel CA, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(11):3975\u20134011. https:\/\/doi.org\/10.1210\/jc.2015-2236","journal-title":"J Clin Endocrinol Metab"},{"key":"5773_CR44","doi-asserted-by":"publisher","unstructured":"Suzuki A, Chen Minjun (2025) Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs. Liver Int 45(4):e16146.\u00a0https:\/\/doi.org\/10.1111\/liv.16146","DOI":"10.1111\/liv.16146"},{"key":"5773_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2022.03.003","volume":"81","author":"V Talaulikar","year":"2022","unstructured":"Talaulikar V (2022) Menopause transition: physiology and symptoms. Best Pract Res Clin Obstet Gynaecol 81:3\u20137. https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.03.003","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"5773_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017416","volume":"10","author":"RC Thurston","year":"2021","unstructured":"Thurston RC, Aslanidou Vlachos HE, Derby CA et al (2021) Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Assoc 10(3):e017416. https:\/\/doi.org\/10.1161\/JAHA.120.017416","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"5773_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18773\/austprescr.2023.005","volume":"46","author":"TR Thynne","year":"2023","unstructured":"Thynne TR, Gabb GM (2023) Limitations of randomised controlled trials as evidence of drug safety. Aust Prescr 46(2):22\u201323. https:\/\/doi.org\/10.18773\/austprescr.2023.005","journal-title":"Aust Prescr"},{"key":"5773_CR48","unstructured":"U.S. Food and Drug Administration (2024a) FDA adds boxed warning to fezolinetant (Veozah) for risk of serious liver injury. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-fezolinetant-veozah-risk-serious-liver-injury. Accessed 20 Apr 2026"},{"key":"5773_CR49","unstructured":"U.S. Food and Drug Administration (2024b) FDA safety communication: liver injury with Veozah (fezolinetant). Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due. Accessed 20 Apr 2026"},{"issue":"11","key":"5773_CR50","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/jwh.2012.3719","volume":"22","author":"J Whiteley","year":"2013","unstructured":"Whiteley J, DiBonaventura MD, Wagner JS, Alvir J, Shah S (2013) The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt) 22(11):983\u2013990. https:\/\/doi.org\/10.1089\/jwh.2012.3719","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"5773_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/AOG.0000000000005914","volume":"146","author":"M Williams","year":"2025","unstructured":"Williams M, Maki PM (2025) A review of cognitive, sleep, and mood changes in the menopausal transition: beyond vasomotor symptoms. Obstet Gynecol 146(3):350\u2013359. https:\/\/doi.org\/10.1097\/AOG.0000000000005914","journal-title":"Obstet Gynecol"},{"issue":"2","key":"5773_CR52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr (2021) Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract 9(2):819-829.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"19","key":"5773_CR53","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acschemneuro.0c00421","volume":"11","author":"WW Zhang","year":"2020","unstructured":"Zhang WW, Wang Y, Chu YX (2020) Tacr3\/NK3R: beyond their roles in reproduction. ACS Chem Neurosci 11(19):2935\u20132943. https:\/\/doi.org\/10.1021\/acschemneuro.0c00421","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"5773_CR54","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","volume":"24","author":"SP Zou","year":"2023","unstructured":"Zou SP, Yang HY, Ouyang ML, Cheng Q, Shi X, Sun MH (2023) A disproportionality analysis of adverse events associated to pertuzumab in the FDA adverse event reporting system (FAERS). BMC Pharmacol Toxicol 24(1):62. https:\/\/doi.org\/10.1186\/s40360-023-00702-w","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05773-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05773-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05773-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:42:45Z","timestamp":1785807765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05773-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":54,"alternative-id":["5773"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05773-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not sought because the study involved only analysis of data obtained from a public database. The study followed regulatory guidelines for postmarketing surveillance data analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to the publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}